REG - Adv Medical Solutns. - Notice of Interim Results

Advanced Medical SolutionsAnnouncement

01/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250901:nRSA3098Xa&default-theme=true

RNS Number : 3098X  Advanced Medical Solutions Grp PLC  01 September 2025

1 September 2025

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Notice of Interim Results

 

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), a world-leading
specialist in tissue-healing technologies, will announce its interim results
for the six months ended 30 June 2025 on Wednesday 17 September 2025.

A briefing for analysts will be held at 10:45am BST on the day of the results.
For further information, please contact AMS@optimumcomms.com.

 

At 2:30pm BST the same day, a presentation by Chris Meredith, Chief Executive
Officer and Eddie Johnson, Chief Financial Officer will be available via
Investor Meet Company.

 

The presentation is open to all existing and potential shareholders and will
also be published on the Company's website following its release.

 

Investors can sign up to Investor Meet Company for free and add Advanced
Medical Solutions plc via:
https://www.investormeetcompany.com/advanced-medical-solutions-group-plc/register-investor
(https://www.investormeetcompany.com/advanced-medical-solutions-group-plc/register-investor)
 
(https://www.investormeetcompany.com/advanced-medical-solutions-group-plc/register-investor)
 

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Optimum Strategic Communications                 Tel: +44 (0) 20 4566 8543
 Mary Clark / Nick Bastin / Isabelle Abdou        AMS@optimumcomms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                         Tel: +44 (0)20 3207 7800
 Toby Flaux / Detlir Elezi / Yasmina Benchekroun

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,600 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOREKLFLEVLFBBK